These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11595884)

  • 1. Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates.
    des Grottes JM; Dumon JC; Body JJ
    Melanoma Res; 2001 Oct; 11(5):477-82. PubMed ID: 11595884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J; Ratcliffe WA; Howell A; Bundred NJ
    Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
    Heatley S
    Int J Palliat Nurs; 2001 Jun; 7(6):301-2, 304-7. PubMed ID: 12066026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
    Weissglas M; Löwik C; Schamhart D; Theuns H; Kurth KH; Papapoulos S
    BJU Int; 2007 Jun; 99(6):1530-3. PubMed ID: 17428243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
    Body JJ; Louviaux I; Dumon JC
    Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
    Gurney H; Grill V; Martin TJ
    Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment.
    Elte JW; Bijvoet OL; Cleton FJ; van Oosterom AT; Sleeboom HP
    Eur J Cancer Clin Oncol; 1986 Apr; 22(4):493-500. PubMed ID: 2942409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
    Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
    Dodwell DJ; Abbas SK; Morton AR; Howell A
    Eur J Cancer; 1991; 27(12):1629-33. PubMed ID: 1782072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.
    Selby PL; Davies M; Marks JS; Mawer EB
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):531-6. PubMed ID: 8548936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
    Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
    Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
    Coleman RE; Rubens RD
    Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of malignant hypercalcaemia with clodronate.
    Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
    Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The significance of early diagnosis of cancer-related hypercalcaemia].
    Radványi I; Csikós A; Balogh S
    Orv Hetil; 2013 Sep; 154(35):1367-73. PubMed ID: 23974972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.